• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Aptose Bioscns (NQ: APTO )

    0.7420 UNCHANGED
    Streaming Delayed Price Updated: 3:41 PM EDT, Jun 24, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,707
    Open 0.7420
    Bid (Size) 0.7304 (1)
    Ask (Size) 0.8887 (1)
    Prev. Close 0.7420
    Today's Range 0.7420 - 0.7420
    52wk Range 0.7320 - 5.580
    Shares Outstanding 93,653,662
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Aptose Announces Results from Annual and Special Meeting of Shareholders
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    Aptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid Congress
    From Aptose Biosciences, Inc.
    Via GlobeNewswire

    Performance

    YTD
    -68.82%
    -68.82%
    1 Month
    -35.15%
    -35.15%
    3 Month
    -50.86%
    -50.86%
    6 Month
    -67.81%
    -67.81%
    1 Year
    -86.10%
    -86.10%

    More News

    Read More
    Aptose Announces Closing of $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    Recap: Aptose Biosciences Q4 Earnings
    Via Benzinga
    Aptose Biosciences's Earnings: A Preview
    Via Benzinga
    Aptose Announces $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    APTO Stock Earnings: Aptose Biosciences Beats EPS for Q1 2024
    Via InvestorPlace
    Aptose Reports Results for the First Quarter 2024
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    Aptose Biosciences: Q3 Earnings Insights
    Via Benzinga
    Aptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    APTO Stock Earnings: Aptose Biosciences Beats EPS for Q4 2023
    Via InvestorPlace
    Aptose Reports Results for the Fourth Quarter and Full Year 2023
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    Aptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    Earnings Scheduled For March 26, 2024
    Via Benzinga
    Aptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    Levi Strauss Layoffs 2024: What to Know About the Latest LEVI Job Cuts
    Via InvestorPlace
    Topics Economy Workforce
    Exposures Economy Layoff
    Why Is SU Group (SUGP) Stock Moving Today?
    Via InvestorPlace
    Topics Initial Public Offering
    Exposures Securities Market
    Why Is Aptose Biosciences (APTO) Stock Down Today?
    Via InvestorPlace
    Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    Why Tellurian Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
    Via InvestorPlace
    Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive Role
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    Aptose Reports Results for the Third Quarter 2023
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    Aptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual Meeting
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.